Home/Pipeline/Baloxavir marboxil (Xofluza®)

Baloxavir marboxil (Xofluza®)

Influenza

MarketedCommercial (via Roche)

Key Facts

Indication

Influenza

Phase

Marketed

Status

Commercial (via Roche)

Company

Shionogi

About Shionogi

Shionogi is a premier, discovery-based Japanese pharmaceutical company with a 65+ year legacy in antibiotic innovation and a mission to supply the best possible medicine to protect patient health. The company has successfully diversified its pipeline beyond its core infectious disease expertise into antivirals, CNS disorders, and rare diseases, while maintaining a steadfast commitment to combating antimicrobial resistance (AMR). Its strategy combines deep in-house R&D capabilities with strategic global partnerships and licensing to accelerate development and commercialize novel therapeutics for serious unmet medical needs worldwide.

View full company profile

Therapeutic Areas

Infectious Diseases Central Nervous System (CNS)Rare Diseases Virology Oncology

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active
Influenza Program	Arisan Therapeutics	Preclinical	Active
Universal Influenza Vaccine	Orlance	Pre-IND	Active
Enhanced Seasonal Influenza Vaccine	Orlance	Research	Active
V3402	Merck	Phase 3	Active, Ongoing